Shorts

1:34
Amy E. Krambeck, MD, on 3- vs 2-lobe enucleation for BPH
a day ago
by
Amy E. Krambeck, MD

0:20
Mohit Khera, MD, MBA, MPH, on why FDA TRT announcement is a “big win”
2 days ago
by
Mohit Khera, MD, MBA, MPH

1:01
The UroOnc Minute: Dr. Alfonso Gómez de Liaño Lista on implications of KEYNOTE-B15
3 days ago
by
Adam B. Weiner, MD(+1 more)

0:21
Jesse N. Mills, MD, on why urologists need to be at the forefront of treating low libido
4 days ago
by
Jesse N. Mills, MD

1:28
Landon Trost, MD, on the significance of the FDA announcement on idiopathic hypogonadism
7 days ago
by
Landon W. Trost, MD

0:43
Mohit Khera, MD, MBA, MPH, reacts to FDA announcement on TRT and idiopathic hypogonadism
8 days ago
by
Mohit Khera, MD, MBA, MPH

1:01
The Expert APProach: Melissa Kestler, DNP, FNP-BC, on working in a stone clinic
8 days ago
by
Joy Maulik, CRNP(+1 more)

0:51
James R. Porter, MD, on the telementoring capabilities of the Hugo RAS
9 days ago
by
James R. Porter, MD

1:12
Pearls & Perspectives: Normalizing sexual wellness conversations
10 days ago
by
Amy M. Pearlman, MD

1:13
Jennifer Miles-Thomas, MD, discusses areas of opportunity for urology APPs
11 days ago
by
Jennifer Miles-Thomas, MD, URPS, MBA

0:59
The Expert APProach: Preparing the Next Generation of APPs
14 days ago
by
Joy Maulik, CRNP(+1 more)

1:03
Akanksha Mehta, MD, on counseling men on vasectomy safety
15 days ago
by
Akanksha Mehta, MD, MS(+1 more)

1:10
Jonathan Anker, MD, on bladder-sparing approach in patients with MIBC
16 days ago
by
Jonathan F. Anker, MD, PhD

1:15
Daniel J. George, MD, on PTEN loss and prostate cancer prognosis
17 days ago
by
Daniel J. George, MD

1:02
Alexandra Drakaki, MD, on misdiagnosis of bladder cancer in women
18 days ago
by
Alexandra Drakaki, MD, PhD

1:02
Pearls & Perspectives: What is “normal” urination frequency?
21 days ago
by
Amy M. Pearlman, MD

1:03
Giulia Almiron da R. Soares on social media and urology recruitment
22 days ago
by
Giulia Almiron da R. Soares

0:23
Jared S. Winoker, MD, on research comparing CVAC 2.0 vs FANS
23 days ago
by
Jared S. Winoker, MD

1:06
James R. Porter, MD, discusses haptics and the Hugo RAS system
24 days ago
by
James R. Porter, MD

0:37
Matthias Saar, MD, outlines the rationale for the phase 2 INDUCTA trial in prostate cancer
25 days ago
by
Matthias Saar, MD

1:13
Pearls & Perspectives: The trouble with voiding diaries
a month ago
by
Amy M. Pearlman, MD

0:29
Is PCNL dead? with Ben H. Chew, MD, MSc, FRCSC
a month ago
by
Ben H. Chew, MD, MSc

1:12
Alicia Morgans, MD, discusses cancer control with enzalutamide, apalutamide
a month ago
by
Alicia Morgans, MD, MPH

1:05
Bogdana Schmidt, MD, MPH, on who could benefit most from ICI plus BCG in high-risk NMIBC
a month ago
by
Bogdana Schmidt, MD, MPH

1:19
Neha Vapiwala, MD, explores the biggest prostate cancer takeaways from ASCO GU 2026
a month ago
by
Neha Vapiwala, MD, FASTRO

1:12
Christopher Pieczonka, MD, on what’s next for NAI plus BCG in BCG-naïve NMIBC
a month ago
by
Christopher Pieczonka, MD

0:42
Sara Coca Membribes, MD, on what’s needed to refine the role of BCG-ICI combinations in NMIBC
a month ago
by
Sara Coca Membribes, MD

0:45
Jean-Nicolas Cornu, MD, PhD, FEBU, on the patient population of VAPEUR-RCT in BPH
a month ago
by
Jean-Nicolas Cornu, MD, PhD, FEBU

0:41
Antoni Vilaseca Cabo, MD, on the pharmacokinetics of erda-iDRS in NMIBC
a month ago
by
Antoni Vilaseca Cabo, MD

0:48
Daniel J. George, MD, on the need for caregiver support in prostate cancer
a month ago
by
Daniel J. George, MD
Advertisement
Advertisement
Trending on Urology Times
1
Fractionated 225Ac–J591 shows early activity, preserved QOL in mCRPC
2
Preclinical data show potential of CD46-targeted combination therapy in prostate cancer
3
David Wise, MD, on the potential role for pasritamig plus docetaxel in mCRPC
4
EAU 2026 Testicular Cancer Guideline reflects key updates in diagnosis and management
5
